A Study to to Determine the Impact of a Mobile Health Application on Rheumatoid Arthritis Shared Decision Making


About this study

The primary objective of this study is to determine the impact of ArthritisPower™ integration into the clinical evaluation of patients with RA on the primary endpoint of clinical improvement as defined by the continuous change in the Clinical Disease Activity Index.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • Age ≥ 18 years.
  • Fulfillment of the ACR/EULAR 2010 classification criteria for RA.
  • Moderate or high disease activity, according to CDAI ≥ 10, at the baseline visit.
  • Intent to modify treatment with oral glucocorticoids or DMARDs (i.e., starting prednisone, changing the dose of prednisone, adding a DMARD, switching to a new DMARD, or changing DMARD dosage) by the patient and HCP.

Exclusion Criteria:

  • Current or previous use of Arthritis Power™ by the patient.
  • Lack of access to an ArthritisPower™ compatible device (e.g., smartphone, tablet, or computer)
  • Inability or unwillingness to participate with using the ArthritisPower™ app for this study.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

John Davis, M.D.

Open for enrollment

Contact information:

Kathleen McCarthy-Fruin



More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer